Optimum Dosage Regimen of Palivizumab?
- 1 June 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 24 (3) , 444-445
- https://doi.org/10.1097/00007691-200206000-00020
Abstract
Palivizumab is a humanized, monoclonal antibody used to protect at-risk infants against respiratory syncytial virus (RSV) infection. The regular dosage scheme causes a low initial trough level and accumulation of the antibody after subsequent injections. Using a simple pharmacokinetic model, the authors devised an alternative dosage regimen that might correct these problems while cutting costs by 35%. To spare health care budgets, dosage schemes for future monoclonal antibodies must be chosen carefully.Keywords
This publication has 4 references indexed in Scilit:
- Therapeutic monoclonal antibodiesThe Lancet, 2000
- Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasiaThe Pediatric Infectious Disease Journal, 1998
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial VirusThe Journal of Infectious Diseases, 1997